Immix Biopharma Inc Dossier - Source-backed chat

Immix Biopharma Inc

IMMXNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.43

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $10.23Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $731.8M

Enterprise Value $506.4M

Shares Outstanding 62.7M diluted

Next Earnings Date31 Mar 2027

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Immix Biopharma is a high-conviction clinical-stage biotechnology play positioned to capture a multi-billion dollar market in relapsed/refractory light chain (AL) Amyloidosis. The company's lead asset, NXC-201, is a sterically-optimized BCMA-targeted CAR-T cell therapy that has demonstrated an exceptional 95% complete response (CR) rate in its registrational NEXICART-2 trial. Backed by FDA Breakthrough Therapy and RMAT designations, Immix is on an accelerated path toward a BLA submission. A recent $150 million capital raise significantly de-risks the company's balance sheet, providing a robust cash runway to fund clinical development and prepare for commercial launch.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets8 analysts · as of 18 Aug 2026

Low · most bearish analyst$14.50

Mean target$19.91

High · most bullish analyst$27.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$5.00

Topline NEXICART-2 results show a decline in durability or unexpected late-stage safety signals, delaying BLA submission. Regulatory approval is delayed, forcing the company to raise additional dilutive capital or face commercial execution challenges as a small biotech self-commercializing a CAR-T therapy.

Base CaseCentral scenario

$19.91

Matches the consensus mean

NXC-201 delivers positive topline results in Q3 2026, leading to a successful BLA submission by early 2027. The drug is approved and launched in late 2027 or early 2028, establishing Immix as the standard of care in relapsed/refractory AL Amyloidosis. The company self-commercializes in the U.S. using its recently expanded commercial leadership team.

Bull CaseUpside scenario

$27.00

NXC-201 achieves rapid FDA approval under Breakthrough Therapy designation, capturing dominant market share in relapsed/refractory AL Amyloidosis due to its superior safety profile (no neurotoxicity) and high complete response rate. The company successfully expands NXC-201 into frontline therapy via a Phase 3 trial and secures a lucrative commercial partnership with a major pharmaceutical firm.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Exceptional clinical efficacy with a 95% complete response rate (19 of 20 patients) in the interim NEXICART-2 trial.
Favorable safety profile with no neurotoxicity observed to date, making it highly suitable for frail AL Amyloidosis patients.
Strong regulatory tailwinds including FDA Breakthrough Therapy, RMAT, and Orphan Drug designations.
Significantly de-risked balance sheet following the closing of a $150 million underwritten offering of common stock in May 2026.

Key Investment Risks

Clinical trial execution and regulatory approval risks inherent to early-stage cell therapies.
Commercialization risk associated with a small biotech self-commercializing a complex CAR-T therapy.
Potential for future equity dilution if clinical timelines are extended or commercial launch costs exceed expectations.

Thesis Invalidation Triggers

Failure of NXC-201 to maintain high complete response rates or durable responses in the final NEXICART-2 topline readout.
Emergence of severe, unexpected adverse events (such as high-grade neurotoxicity or severe cytokine release syndrome) in clinical trials.
Regulatory rejection or significant delays in the BLA review process by the FDA.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.